Cardiff Oncology is a clinical-stage biotech with no approved products or revenue, focused entirely on developing onvansertib, an oral, selective PLK1 inhibitor for cancer treatment. PLK1 is a protein that cancer cells depend on for cell division, making it a validated oncology target. Cardiff's strategy is to combine onvansertib with existing standard-of-care chemotherapy regimens to produce synergistic anti-tumor effects. Cardiff's lead program targets RAS-mutated metastatic colorectal cancer (mCRC), a large patient population since more than half of colorectal tumors carry a RAS mutation. Cardiff is running CRDF-004, a Phase 2 randomized trial evaluating onvansertib added to first-line chemotherapy; if successful, Cardiff plans to initiate a Phase 3 registrational trial targeting FDA approval via an accelerated approval pathway using objective response rate as an interim endpoint. Beyond mCRC, Cardiff supports investigator-initiated trials in pancreatic, lung, breast, and blood cancers as signal-finding studies, though mCRC is the clear priority. Cardiff funds operations through equity raises and has no product revenue. Cardiff has partnered with Pfizer Ignite for clinical operations of CRDF-004, but retains full ownership of onvansertib and bears all trial costs. Cardiff's near-term path is highly binary, hinging on CRDF-004 data supporting a Phase 3 trial.